Please wait while the transcript is being prepared...
0:00
Ladies and gentlemen,
my name is Kim Brosen.
I'm a professor of
clinical pharmacology
at the University of Southern
Denmark in Odense, Denmark.
I'm going to talk to you about
the clinical significance
of enzyme induction and inhibition.
0:17
There is a Danish cartoon
made by a Danish cartoonist
called Robert Storm Petersen.
It shows a physician who hands
a prescription to a patient
and says to the patient, "If this
drug doesn't help, then come back,
and I can prescribe
you something else."
And then the patient
says: "Why don't
I get something else right away?"
And what we're going
to talk about today
is related to this everyday
clinical situation
that the outcome of a
treatment is unpredictable
because patients are different.
0:49
Patients are different both
in their pharmacokinetics
and pharmacodynamics because there
are different host factors
that influence the actions of drugs.
Patients live in
different environments.
And patients are
genetically different.
And these three domains
certainly also influence
differences in drug metabolism.
1:11
Drug-drug interactions are something
that can occur when two or more
drugs are given concomitantly.
And what it means is that one
perpetrator drug changes the effect
of another victim drug
in a way which
is not beneficial to the patient.
1:28
Usually, drugs are developed
and made in such a way
that the likelihood of giving
interactions with other drugs
is minimized.
So therefore, it's quite
common in clinical practice
that drugs can be combined without
any drug-drug interactions.
Or there can be clinically
unimportant drug interaction.
It's rather unusual that there
are clinically important drug interactions,
which can be
coped with by adjusting the dose
or changing the dose regimen.
And very rarely, drug-drug
interaction is so dangerous
that two drugs cannot be combined.
